Fill It Pack It Inc
Letter data
- Company
- Fill It Pack It Inc
- Recipient
- Mr. Robert L. Miller | Vice President and Co-owner | Fill It Pack It Inc | 2555 E. Del Amo Blvd. | Compton | , | CA | 90221 | United States
- Issue date
- 2021-07-19
- Posted date
- Not available
- FDA office
- Division of Pharmaceutical Quality Operations IV
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 570946
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Fill It Pack It Inc
MARCS-CMS 570946 —
July 19, 2021
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
Via Email Delivery Confirmation
Product:
Drugs
Recipient:
Recipient Name
Mr. Robert L. Miller
Recipient Title
Vice President and Co-owner
Fill It Pack It Inc
2555 E. Del Amo Blvd.
Compton
,
CA
90221
United States
Issuing Office:
Division of Pharmaceutical Quality Operations IV
United States
949-608-2900
Dear Mr. Miller:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your response to our Warning Letter (Ref CMS 570946) dated May 2, 2019. Based on our evaluation, it appears that you have adequately addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV
Content current as of:
07/21/2021
Regulated Product(s)
Drugs